文献速递冠心病血脂与心血管预防

心肌梗死后接种流感疫苗:随机双盲安慰剂对照多中心试验

Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.
PubMed 文献 · Circulation · 2021-08-30

该随机双盲试验将2571例近期心梗(99.7%)或高危稳定冠心病(0.3%)患者分配至灭活流感疫苗组或生理盐水安慰剂组,主要终点为12个月全因死亡、心梗或支架血栓复合终点。因COVID-19疫情提前终止,改良意向治疗分析2532例。疫苗组主要终点发生率5.3% vs 安慰剂7.2%(HR 0.72,95%CI 0.52-0.99,P=0.040),全因死亡和心血管死亡风险亦显著降低。

要点

  • 心梗后早期接种灭活流感疫苗可降低12个月全因死亡、心梗或支架血栓复合终点风险。
  • 疫苗组全因死亡(2.9% vs 4.9%,HR 0.59)和心血管死亡(2.7% vs 4.5%,HR 0.59)均显著低于安慰剂组。
  • 心肌梗死发生率两组无显著差异(2.0% vs 2.4%,HR 0.86,95%CI 0.50-1.46,P=0.57)。

核心结论

  • 心梗后或高危冠心病患者早期接种流感疫苗,12个月全因死亡、心梗或支架血栓复合终点风险低于安慰剂。
  • 全因死亡和心血管死亡风险亦显著低于安慰剂组。

研究设计与样本

  • 研究者发起的随机双盲安慰剂对照多中心试验,比较灭活流感疫苗与生理盐水安慰剂。
  • 2016年10月1日至2020年3月1日在8国30中心随机2571例,99.7%为心梗后,0.3%为高危稳定冠心病。
  • 因COVID-19疫情数据安全监查委员会建议在达到预设样本量前终止;2532例接受治疗并纳入改良意向治疗分析(疫苗组1272例,安慰剂组1260例)。

主要发现

  • 12个月主要复合终点:疫苗组67例(5.3%),安慰剂组91例(7.2%),HR 0.72(95%CI 0.52-0.99),P=0.040。
  • 全因死亡:疫苗组2.9%,安慰剂组4.9%,HR 0.59(95%CI 0.39-0.89),P=0.010。
  • 心血管死亡:疫苗组2.7%,安慰剂组4.5%,HR 0.59(95%CI 0.39-0.90),P=0.014。
  • 心肌梗死:疫苗组2.0%,安慰剂组2.4%,HR 0.86(95%CI 0.50-1.46),P=0.57。

临床怎么用

  • 对于近期心肌梗死或高危稳定冠心病患者,可考虑早期接种灭活流感疫苗以降低复合心血管事件及死亡风险。

局限性

  • 试验因COVID-19疫情提前终止,未达到预设样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease. METHODS: We conducted an investigator-initiated, randomized, double-blind trial to compare inactivated influenza vaccine with saline placebo administered shortly after myocardial infarction (MI; 99.7% of patients) or high-risk stable coronary heart disease (0.3%). The primary end point was the composite of all-cause death, MI, or stent thrombosis at 12 months. A hierarchical testing strategy was used for the key secondary end points: all-cause death, cardiovascular death, MI, and stent thrombosis. RESULTS: Because of the COVID-19 pandemic, the data safety and monitoring board recommended to halt the trial before attaining the prespecified sample size. Between October 1, 2016, and March 1, 2020, 2571 participants were randomized at 30 centers across 8 countries. Participants assigned to influenza vaccine totaled 1290 and individuals assigned to placebo equaled 1281; of these, 2532 received the study treatment (1272 influenza vaccine and 1260 placebo) and were included in the modified intention to treat analysis. Over the 12-month follow-up, the primary outcome occurred in 67 participants (5.3%) assigned influenza vaccine and 91 participants (7.2%) assigned placebo (hazard ratio, 0.72 [95% CI, 0.52-0.99]; P=0.040). Rates of all-cause death were 2.9% and 4.9% (hazard ratio, 0.59 [95% CI, 0.39-0.89]; P=0.010), rates of cardiovascular death were 2.7% and 4.5%, (hazard ratio, 0.59 [95% CI, 0.39-0.90]; P=0.014), and rates of MI were 2.0% and 2.4% (hazard ratio, 0.86 [95% CI, 0.50-1.46]; P=0.57) in the influenza vaccine and placebo groups, respectively. CONCLUSIONS: Influenza vaccination early after an MI or in high-risk coronary heart disease resulted in a lower risk of a composite of all-cause death, MI, or stent thrombosis, and a lower risk of all-cause death and cardiovascular death, as well, at 12 months compared with placebo. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02831608.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Fröbert O, Götberg M, Erlinge D, et al. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021. PMID: 34459211. doi:10.1161/CIRCULATIONAHA.121.057042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。